2,4,6-triisopropyl-N'-(1-(4-methoxyphenyl)ethylidene)benzenesulfonohydrazide | 102387-06-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4,6-triisopropyl-N'-(1-(4-methoxyphenyl)ethylidene)benzenesulfonohydrazide
• 英文别名: 4-methoxyacetophenone 2,4,6-triisopropylbenzenesulphonylhydrazone；N-[1-(4-methoxyphenyl)ethylideneamino]-2,4,6-tri(propan-2-yl)benzenesulfonamide
• CAS: 102387-06-4
• 化学式: C₂₄H₃₄N₂O₃S
• 分子量: 430.612
• InChiKey: LBZZNTNGNVXBAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4,6-triisopropyl-N'-(1-(4-methoxyphenyl)ethylidene)benzenesulfonohydrazide 在 正丁基锂 、 四甲基乙二胺 作用下， 以 正己烷 为溶剂， 反应 2.5h， 生成 1-(4-methoxyphenyl)vinyllithium
  参考文献：
  名称：

  [EN] 1-(2-AMINO-1-PHENYL-ETHYL) 1- SILACYCLOHEXAN-1- OL DERIVATIVES AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT
  [FR] DERIVES DE 1-(2-AMINO-1-PHENYL-ETHYL)-SILACYCLOHEXAN-1-OL ET UTILISATION DESDITS DERIVES POUR PREPARER UN MEDICAMENT

  摘要：

  从中选择的化合物：(RS)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；(R)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；以及(S)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；或其药学上可接受的盐或可水解为上述定义的化合物的前药形式。

  公开号：

  WO2004094436A1
• 作为产物：
  描述：

  2,4,6-三异丙基苯磺酰基肼 、 对甲氧基苯乙酮 生成 2,4,6-triisopropyl-N'-(1-(4-methoxyphenyl)ethylidene)benzenesulfonohydrazide
  参考文献：
  名称：

  3-phenyl-2-propeneamine derivatives, their preparation and compositions

  摘要：

  本发明提供式（I）化合物： ##STR1## 其中R=H、卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基或CF3，R3=H或烷基，R4和R5=H且R1和R2=H或烷基，任选被2至4个碳的烯基取代；或者R1和R2一起形成含有4至7个环成员的饱和杂环环，任选含有另一个杂原子如O、S或N，任选被烷基取代；或者R4=H，R1=H或烷基，R2和R5一起形成3至4个碳的亚烷基基团；（i）A=烷基或苯基，未被取代或被一个或两个选自卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基、NO2或CF3的取代基取代；或者A=吡啶基、苄基或3至6个碳的环烷基；Y=S、SO或SO2或基团： ##STR2## 其中R6=H或烷基，R7=H或烷基羰基、烷氧基羰基、烷基氨基羰基或苯甲酰基，任选被一个或两个卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基、NO2或CF3基团取代；（ii）或者Y和A一起形成1-羟基环烷基基团，其环含有5或6个碳，任选与苯环稠合；其中烷基基团和烷基部分含有1至4个碳，可以是直链或支链；本发明涉及所有可能的几何异构体和光学异构体以及它们的混合物。这些化合物作为抗抑郁药有用。

  公开号：

  US04686309A1

文献信息

• Palladium-Catalyzed Dearomative Arylvinylation Reaction of Indoles with <i>N</i>-Arylsulfonylhydrazones
  作者：Ren-Xiao Liang、Ke Wang、Quan Wu、Wei-Jian Sheng、Yi-Xia Jia

  DOI：10.1021/acs.organomet.9b00112

  日期：2019.10.28

  arylvinylation reaction of indoles with N-arylsulfonylhydrazones as coupling partners is developed, which proceeds via a domino sequence involving dearomative carbopalladation, Pd-carbene migratory insertion, and regioselective β-hydride elimination. A range of 3-vinylindolines bearing vicinal quaternary and tertiary carbon stereocenters is achieved in moderate yields. The enantioselective reaction was established

  进行了吲哚与N-芳基磺酰基hydr作为偶合伴侣的Pd催化脱芳香芳基乙烯基化反应，该过程通过涉及脱芳香碳巴巴拉德，Pd-卡宾迁移插入和区域选择性β-氢化物消除的多米诺序列进行。以中等收率获得了一系列带有邻位的季碳和叔碳立体中心的3-乙烯基吲哚啉。对映选择性反应是通过使用基于手性BINOL的亚磷酰胺配体建立的，从而产生了具有良好对映体比率和出色的非对映选择性的芳基乙烯基化产物。
• Self‐Sustaining Fluorination of Active Methylene Compounds and High‐Yielding Fluorination of Highly Basic Aryl and Alkenyl Lithium Species with a Sterically Hindered <i>N</i> ‐Fluorosulfonamide Reagent
  作者：Yuhao Yang、Gerald B. Hammond、Teruo Umemoto

  DOI：10.1002/anie.202211688

  日期：2022.10.24

  By developing a sterically hindered fluorinating agent, N-fluoro-N-(tert-butyl)-tert-butanesulfonamide (NFBB), we discovered a conceptually novel base-catalyzed, self-sustaining fluorination of active methylene compounds and achieved an unprecedented high-yield fluorination of highly basic (hetero)aryl and alkenyl lithium species.

  通过开发空间位阻氟化剂N-氟-N- (叔丁基)-叔丁磺酰胺(NFBB)，我们发现了一种概念性新颖的碱催化、活性亚甲基化合物自持氟化反应，并实现了前所未有的高产率。产生高碱性（杂）芳基和烯基锂物种的氟化。
• A Novel Palladium-Catalyzed Asymmetric Cyclocarbonylation of Allylic Alcohols to γ-Butyrolactones
  作者：Wing-Yiu Yu、Corinne Bensimon、Howard Alper

  DOI：10.1002/chem.19970030313

  日期：——

  AbstractA catalyst system based on [Pd2(dba)3]·CHCl3/(‐)‐BPPM has been found to effect asymmetric cyclocarbonylation of certain prochiral allylic alcohols to produce good yields of optically enriched γ‐butyrolactones. The reaction was performed under an atmosphere of H2 (400 psi) and CO (400 psi) at 100°C in methylene chloride for 48 hours. Asymmetric cyclocarbonylation of allylic alcohols with aliphatic substituents proceeded with moderate enantioselectivities (ee = 25–43%). However, enantiomeric excesses of up to 83% were obtained for substrates containing aromatic substituents, in which case the ee was found to be more sensitive to steric, rather than to electronic factors. Recrystallization of the lactones containing an aromatic group from a mixture of CH2Cl2/Et2O/hexanes (0.5/1.0/8.5), by slow evaporation of the solvent or at low temperature, improved the enantiopurities to >98% ee on a reproducible basis. The asymmetric center of the aromatic lactones was assigned the (S)‐configuration based on the X‐ray crystal structure analysis of enantiopure (S)‐(+)‐3,3‐dimethyl‐2‐(2′‐methylphenyl)‐γ‐butyrolactone (2k). A hydridopalladium intermediate is believed to play a key role in this reaction. Enantioselectivity is thought to be brought about by the preferential formation of 6b. The carbon skeleton of 6b fits into the chiral scaffold of (‐)‐BPPM.
• [EN] 1-(2-AMINO-1-PHENYL-ETHYL) 1- SILACYCLOHEXAN-1- OL DERIVATIVES AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT<br/>[FR] DERIVES DE 1-(2-AMINO-1-PHENYL-ETHYL)-SILACYCLOHEXAN-1-OL ET UTILISATION DESDITS DERIVES POUR PREPARER UN MEDICAMENT
  申请人：AMEDIS PHARM LTD

  公开号：WO2004094436A1

  公开（公告）日：2004-11-04

  A compound selected from: (RS)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol (S)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)- 1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)- 1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-dimethyl amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1,4-diol; (R)-1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-l,4-diol; and (S)-1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1,4-diol; or a pharmaceutically acceptable salt thereof or a prodrug form that is hydrolysable to a compound as defined above.

  从中选择的化合物：(RS)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；(R)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；以及(S)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；或其药学上可接受的盐或可水解为上述定义的化合物的前药形式。
• 3-phenyl-2-propeneamine derivatives, their preparation and compositions
  申请人：Rhone-Poulenc Sante

  公开号：US04686309A1

  公开（公告）日：1987-08-11

  The invention provides compounds of formula: ##STR1## in which R=H, halogen, alkyl, alkyloxy, alkythio, NH.sub.2, alkylamino, dialkylamino or CF.sub.3, R.sub.3 =H or alkyl, either R.sub.4 and R.sub.5 =H and R.sub.1 and R.sub.2 =H or alkyl, optionally substituted by alkenyl (2 to 4 C) or alternatively R.sub.1 and R.sub.2 form together a saturated heterocyclic ring containing 4 to 7 ring members and optionally containing another heteroatom such as O, S or N optionally substituted by alkyl, or R.sub.4 =H, R.sub.1 =H or alkyl and R.sub.2 and R.sub.5 together form an alkylene (3 to 4 C) radical and (i) either A=alkyl or phenyl which is unsubstituted or substituted by one or two substituents chosen from halogen, alkyl, alkyloxy, alkylthio, NH.sub.2, alkylamino, dialkylamino, NO.sub.2 or CF.sub.3 or alternatively A=pyridyl, benzyl or cycloalkyl (3 to 6C), Y=S, SO or SO.sub.2 or a radical: ##STR2## in which R.sub.6 =H or alkyl and R.sub.7 =H or alkylcarbonyl, alkyloxycarbonyl, alkylaminocarbonyl or benzoyl, optionally substituted by one or two halogen, alkyl, alkyloxy, alkylthio, NH.sub.2, alkylamino, dialkylamino, NO.sub.2 or CF.sub.3 groups, (ii) or Y and A together form a 1-hydroxycycloalkyl radical, the ring of which contains 5 or 6 C, optionally joined to a benzene ring, it being understood that the alkyl radicals and alkyl parts contain 1 to 4 C as a straight or branched chain, and that the invention relates to all the possible geometric and optical isomers as well as their mixtures. These compounds are useful as antidepressants.

  本发明提供式（I）化合物： ##STR1## 其中R=H、卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基或CF3，R3=H或烷基，R4和R5=H且R1和R2=H或烷基，任选被2至4个碳的烯基取代；或者R1和R2一起形成含有4至7个环成员的饱和杂环环，任选含有另一个杂原子如O、S或N，任选被烷基取代；或者R4=H，R1=H或烷基，R2和R5一起形成3至4个碳的亚烷基基团；（i）A=烷基或苯基，未被取代或被一个或两个选自卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基、NO2或CF3的取代基取代；或者A=吡啶基、苄基或3至6个碳的环烷基；Y=S、SO或SO2或基团： ##STR2## 其中R6=H或烷基，R7=H或烷基羰基、烷氧基羰基、烷基氨基羰基或苯甲酰基，任选被一个或两个卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基、NO2或CF3基团取代；（ii）或者Y和A一起形成1-羟基环烷基基团，其环含有5或6个碳，任选与苯环稠合；其中烷基基团和烷基部分含有1至4个碳，可以是直链或支链；本发明涉及所有可能的几何异构体和光学异构体以及它们的混合物。这些化合物作为抗抑郁药有用。